New Delhi: Peer-review publication, Clinical Infectious Diseases, has noted that Covaxin demonstrates protection against the new Covid-19 variants.
Also Read
A modest reduction in neutralisation by a factor of 1.95 was observed against B1617 variant compared to vaccine variant.
Despite this reduction, neutralising titre levels with B 1617 remain above levels expected to be protective.
No difference in neutralisation between B 117 first identified in the UK and vaccine strain was observed.
The study was conducted in collaboration with National Institute of Virology and Indian Council of Medical Research.